Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al Journal Article
| Author: | Saltz, L. B. |
| Article Title: | Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al |
| Keywords: | cancer chemotherapy; bevacizumab; antineoplastic agent; letter; progression free survival; drug cost; reimbursement; human; priority journal |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 32 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-11-10 |
| Start Page: | 3843 |
| Language: | English |
| DOI: | 10.1200/jco.2015.62.9287 |
| PROVIDER: | scopus |
| PUBMED: | 26304894 |
| DOI/URL: | |
| Notes: | Correspondence -- Export Date: 2 December 2015 -- Source: Scopus |
